ID   FT246
AC   CVCL_UH61
SY   iFTSEC246; hTERT FT 246
DR   ATCC; CRL-3448
DR   GEO; GSM1663016
DR   GEO; GSM1663017
DR   GEO; GSM1663018
DR   GEO; GSM1663019
DR   GEO; GSM1663020
DR   GEO; GSM1663021
DR   GEO; GSM1663022
DR   GEO; GSM1663023
DR   Wikidata; Q93557163
RX   PubMed=22936217;
RX   PubMed=25804953;
RX   PubMed=26364602;
RX   PubMed=30487138;
CC   Doubling time: ~32 hours (ATCC=CRL-3448).
CC   Knockout cell: Method=shRNA knockdown; HGNC; HGNC:11998; TP53.
CC   Genetic integration: Method=Transduction; Gene=HGNC; HGNC:1773; CDK4 (Note=With p.Arg24Cys).
CC   Genetic integration: Method=Transduction; Gene=HGNC; HGNC:11730; TERT.
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR).
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: H3K4me1 ChIP-seq epigenome analysis.
CC   Derived from site: In situ; Fallopian tube; UBERON=UBERON_0003889.
CC   Cell type: Fallopian tube secretory epithelial cell; CL=CL_4030006.
ST   Source(s): ATCC=CRL-3448
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 9,10
ST   D16S539: 9,13
ST   D5S818: 11,12
ST   D7S820: 11
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 17
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Telomerase immortalized cell line
DT   Created: 25-02-19; Last updated: 19-12-24; Version: 10
//
RX   PubMed=22936217; DOI=10.1038/nprot.2012.097; PMCID=PMC7433321;
RA   Karst A.M., Drapkin R.I.;
RT   "Primary culture and immortalization of human fallopian tube secretory
RT   epithelial cells.";
RL   Nat. Protoc. 7:1755-1764(2012).
//
RX   PubMed=25804953; DOI=10.1093/hmg/ddv101; PMCID=PMC4459387;
RA   Coetzee S.G., Shen H.C., Hazelett D.J., Lawrenson K.,
RA   Kuchenbaecker K., Tyrer J.P., Rhie S.K., Levanon K., Karst A.M.,
RA   Drapkin R.I., Ramus S.J., Couch F.J., Offit K., Chenevix-Trench G.,
RA   Monteiro A.N.A., Antoniou A., Freedman M.L., Coetzee G.A.,
RA   Pharoah P.D.P., Noushmehr H., Gayther S.A.;
RG   Consortium of Investigators of Modifiers of BRCA1/2;
RG   Ovarian Cancer Association Consortium;
RT   "Cell-type-specific enrichment of risk-associated regulatory elements
RT   at ovarian cancer susceptibility loci.";
RL   Hum. Mol. Genet. 24:3595-3607(2015).
//
RX   PubMed=26364602; DOI=10.1038/onc.2015.288; PMCID=PMC4791205;
RA   Hua G.-H., Lv X.-M., He C.-B., Remmenga S.W., Rodabaugh K.J.,
RA   Dong J.-X., Yang L., Lele S.M., Yang P., Zhou J., Karst A.M.,
RA   Drapkin R.I., Davis J.S., Wang C.;
RT   "YAP induces high-grade serous carcinoma in fallopian tube secretory
RT   epithelial cells.";
RL   Oncogene 35:2247-2265(2016).
//
RX   PubMed=30487138; DOI=10.1158/0008-5472.CAN-17-3864; PMCID=PMC6359979;
RA   Buckley M.A., Woods N.T., Tyrer J.P., Mendoza-Fandino G.,
RA   Lawrenson K., Hazelett D.J., Najafabadi H.S., Gjyshi A.,
RA   Carvalho R.S., Lyra P.C. Jr., Coetzee S.G., Shen H.C., Yang A.W.,
RA   Earp M.A., Yoder S.J., Risch H., Chenevix-Trench G., Ramus S.J.,
RA   Phelan C.M., Coetzee G.A., Noushmehr H., Hughes T.R., Sellers T.A.,
RA   Goode E.L., Pharoah P.D.P., Gayther S.A., Monteiro A.N.A.;
RT   "Functional analysis and fine mapping of the 9p22.2 ovarian cancer
RT   susceptibility locus.";
RL   Cancer Res. 79:467-481(2019).
//